Polyclonal Human Immunoglobulin for EGFR Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments relying on surgery, chemotherapy, and radiotherapy are evolving with the integration of immunotherapies, but there is a need for effective immunoglobulin products targeting Epidermal Growth Factor Receptor (EGFR) for therapeutic use in cancer patients.
Innovation Solution
Development of a polyclonal human immunoglobulin product derived from genetically engineered ungulates, specifically designed to bind EGFR, which exhibits complement-dependent cytotoxicity, antibody-dependent cellular toxicity, and inhibits tumor cell growth by blocking the EGF receptor signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody therapy is used to target EGFR, then specific binding to EGFR is achieved, but therapeutic efficacy and safety are limited compared to polyclonal immunoglobulin
Solution Approach 1:
The patent changes the fundamental parameter of immunoglobulin structure from monoclonal (single antibody sequence) to polyclonal (mixture of multiple antibody sequences with different specificities). This parameter change enables broader EGFR coverage and enhanced therapeutic efficacy while maintaining human sequence identity for safety
Solution Approach 2:
The patent creates a composite immunoglobulin product comprising multiple different human immunoglobulin sequences that collectively target EGFR. This composite approach combines the binding capabilities of multiple antibodies into a single therapeutic formulation, achieving superior efficacy compared to single monoclonal antibodies
2Adaptability or versatility
If polyclonal immunoglobulin from non-human sources is used, then broad EGFR binding is achieved, but human safety is compromised due to non-human sequences
Solution Approach 1:
The patent applies local quality by ensuring that the variable regions (antigen-binding sites) of the polyclonal immunoglobulin have human sequences for safety, while the overall polyclonal mixture provides diverse EGFR binding. This localized humanization of critical regions resolves the conflict between binding versatility and human compatibility
3Ease of manufacture
If traditional cancer treatments (surgery, chemotherapy, radiotherapy) are used, then established therapeutic options are available, but effectiveness against EGFR+ cancer is limited
Solution Approach 1:
The patent introduces polyclonal human immunoglobulin as an intermediary therapeutic agent that specifically targets EGFR-expressing cancer cells. This immunoglobulin acts as a mediator between the immune system and cancer cells, providing targeted therapy that bridges the gap between traditional treatments and immunotherapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyclonal human immunoglobulin product demonstrates substantial therapeutic benefits by effectively binding to EGFR-expressing cancer cells, inhibiting tumor growth, and offering improved safety profiles compared to monoclonal antibody therapies.
Implementation Method 1
a population of human immunoglobulins that specifically binds the Epidermal Growth Factor Receptor (EGFR)
Implementation Method 2
the population of human immunoglobulins exhibit complement-dependent-cytotoxicity (CDC) activity
Implementation Method 3
the population of human immunoglobulins exhibit antibody-dependent cellular toxicity (ADCC) activity
Data Source
AI summary
Provided are human polyclonal immunoglobulin products specific for Epidermal Growth Factor Receptor (EGFR) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.